Literature DB >> 11734427

Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline.

L J Dowson1, P J Guest, R A Stockley.   

Abstract

The FEV(1) declines rapidly in alpha(1)-antitrypsin deficiency (alpha(1)-ATD) but less is known about other measures of disease severity and the factors, other than smoking, that are associated with progression of emphysema. The natural history of alpha(1)-ATD was studied prospectively in 43 patients with the PiZ phenotype and emphysema at a single center over 2 yr. The mean +/- SE change in FEV(1) was -67 +/- 14 ml/yr, accompanied by a reduction in transfer factor (mean change in diffusing capacity of the lung for CO [DL(CO)] -1.07 +/- 0.21 ml/min/mm Hg/yr; p < 0.001) and lung density in the upper zones as assessed by quantitative high-resolution computed tomography (HRCT) (mean change in voxel index 2.8 +/- 0.6%/yr; p < 0.001). The decline in FEV(1) related to baseline FEV(1) (r = -0.56, p < 0.001), bronchodilator reversibility (r = 0.52, p < 0.001), and (for patients with FEV(1) > 35% predicted) exacerbation frequency (r = -0.38, p = 0.02). There was also a decline in the St. George's Respiratory Questionnaire (SGRQ) Activity score (mean change -4.3 +/- 1.2 units/yr, p < 0.001) that correlated with FEV(1) decline (r = 0.45, p = 0.002). Progression of emphysema in alpha(1)-ATD is dependent on baseline physiology and exacerbation frequency and may be detected by several different measurements of which HRCT density mask analysis and DL(CO) appear most sensitive.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11734427     DOI: 10.1164/ajrccm.164.10.2106036

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  38 in total

1.  Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2.

Authors:  Yoshihiko Ikeda; Angelo M Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Souheil El-Chemaly; Bernadette R Gochuico; Rose M May; Olanda M Hathaway; Shaowei Li; Ji-an Wang; Thomas N Darling; Mario Stylianou; Joel Moss
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-10-29       Impact factor: 5.464

2.  Validation of computed tomographic lung densitometry for monitoring emphysema in alpha1-antitrypsin deficiency.

Authors:  D G Parr; B C Stoel; J Stolk; R A Stockley
Journal:  Thorax       Date:  2006-03-14       Impact factor: 9.139

Review 3.  Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control.

Authors:  Urs Frey; Béla Suki
Journal:  Lancet       Date:  2008-09-20       Impact factor: 79.321

Review 4.  Airway hydration and COPD.

Authors:  Arunava Ghosh; R C Boucher; Robert Tarran
Journal:  Cell Mol Life Sci       Date:  2015-06-12       Impact factor: 9.261

5.  CT Scanning in COPD - Is it Time to Move On?

Authors:  Carolyn E Come; George R Washko
Journal:  Chronic Obstr Pulm Dis       Date:  2015-07-14

6.  Assessment of lung volume collapsibility in chronic obstructive lung disease patients using CT.

Authors:  Shinjini Kundu; Suicheng Gu; Joseph K Leader; John R Tedrow; Frank C Sciurba; David Gur; Naftali Kaminski; Jiantao Pu
Journal:  Eur Radiol       Date:  2013-03-15       Impact factor: 5.315

7.  Chronic obstructive pulmonary disease: lobe-based visual assessment of volumetric CT by Using standard images--comparison with quantitative CT and pulmonary function test in the COPDGene study.

Authors:  Song Soo Kim; Joon Beom Seo; Ho Yun Lee; Dipti V Nevrekar; Anna V Forssen; James D Crapo; Joyce D Schroeder; David A Lynch
Journal:  Radiology       Date:  2012-12-06       Impact factor: 11.105

Review 8.  Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history.

Authors:  M Needham; R A Stockley
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

9.  Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency.

Authors:  David G Parr; Asger Dirksen; Eeva Piitulainen; Chunqin Deng; Marion Wencker; Robert A Stockley
Journal:  Respir Res       Date:  2009-08-13

10.  Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank.

Authors:  Adriano R Tonelli; Farshid Rouhani; Ning Li; Pam Schreck; Mark L Brantly
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.